Ophthalmology – Guillain–Barré Syndrome and Fisher Syndrome Variant

Basics

Description

Guillain–Barré syndrome (GBS) is an acute immune-mediated inflammatory disorder predominantly affecting the peripheral nerves and nerve roots. The classic demyelinating form is also called acute inflammatory demyelinating polyneuropathy (AIDP).

The clinical spectrum includes:

• Classic Guillain–Barré syndrome
• Fisher syndrome (FS), also called Miller Fisher syndrome
• Bickerstaff brainstem encephalitis (BBE)
• Other less common GBS variants

The disorder is frequently postinfectious, resulting from an autoimmune response triggered by a preceding infection.

⚠️ Clinical Alert: Ascending paralysis can progress rapidly and involve the respiratory muscles, resulting in respiratory failure. Respiratory and autonomic monitoring is essential.

Epidemiology

The incidence of GBS is approximately 0.6–4 cases per 100,000 population.

Fisher syndrome represents approximately 1–7% of GBS-spectrum cases in Western countries, but may account for up to 25% in Japan.

Men are affected more frequently than women.

GBS can occur at any age but is most frequent from the third through seventh decades. Fisher syndrome has been reported to show peaks in approximately the fourth and sixth decades.

Risk Factors

Important precipitating factors include preceding infection, surgery, and occasionally immunization.

Antecedent Infections

Approximately two-thirds of patients report an infection before neurologic symptoms begin.

Important organisms include:

• Campylobacter jejuni
• Haemophilus influenzae
• Cytomegalovirus
• Epstein–Barr virus
• Other viral respiratory or gastrointestinal infections

Pathophysiology

GBS is primarily an immune-mediated attack on peripheral nerves.

An infectious or other antigenic exposure triggers antibodies and cellular immune responses that cross-react with components of peripheral nerves through molecular mimicry.

This can produce:

• Peripheral nerve demyelination
• Perivascular inflammatory infiltration
• Conduction block
• Variable secondary axonal injury
• Wallerian degeneration in severe disease

Certain GBS variants are more strongly associated with antibodies directed against specific neuronal gangliosides.

Anti-GQ1b Antibodies

Anti-GQ1b antibodies are particularly important in Fisher syndrome.

They are present in the great majority of patients with typical Fisher syndrome and correlate strongly with ophthalmoplegia and ataxia.

Etiology

The underlying mechanism is an autoimmune response following exposure to an antigen, usually from an antecedent infection.

The resulting immune response mistakenly targets peripheral nerve components.

Diagnosis

History

Classic GBS usually begins with acute or subacute weakness.

Weakness typically starts in the distal lower extremities and progresses proximally over hours to days, producing the characteristic ascending paralysis.

Sensory symptoms such as numbness, paresthesias, or neuropathic discomfort may occur but are usually less prominent than motor weakness.

As the disease progresses, cranial nerves may become involved, producing:

• Facial weakness
• Ptosis
• Diplopia
• Dysphagia
• Dysarthria

Bulbar and respiratory involvement can become life-threatening.

Fisher Syndrome Presentation

Fisher syndrome commonly presents differently from classic ascending GBS.

The characteristic initial complaints are:

• Diplopia
• Gait instability or ataxia

Physical Examination

Classic GBS

The characteristic neurologic findings include:

• Symmetric, usually ascending weakness
• Reduced or absent deep tendon reflexes
• Cranial nerve involvement
• Facial weakness
• Bulbar weakness
• Possible respiratory muscle weakness

Severe bulbar or respiratory weakness can result in apnea and respiratory failure.

Fisher Syndrome – Classic Triad

The classic Fisher syndrome triad consists of:

1. Ophthalmoplegia

Ptosis and ophthalmoparesis are prominent and may progress to essentially complete bilateral ophthalmoplegia.

2. Ataxia

Patients develop significant gait and limb ataxia.

3. Areflexia

Deep tendon reflexes are reduced or absent.

Ophthalmoplegia + Ataxia + Areflexia = Fisher syndrome

Ophthalmic Manifestations

Ptosis and ophthalmoparesis may occur throughout the GBS spectrum but are particularly characteristic of Fisher syndrome.

The ophthalmoplegia can be complex and may demonstrate both peripheral and central patterns.

Findings can include:

• Third cranial nerve paresis
• Fourth cranial nerve paresis
• Sixth cranial nerve paresis
• Symmetric ophthalmoplegia that does not correspond to an individual cranial nerve
• Internuclear ophthalmoplegia
• Vertical gaze abnormalities
• Nystagmus
• Supranuclear gaze abnormalities
• Ptosis

GBS, particularly Fisher syndrome, is an important cause of complete bilateral ophthalmoplegia.

Pupillary Abnormalities

Pupillary involvement can occur.

Some patients develop mydriasis with a poorly reactive pupil.

Light-near dissociation may also occur, in which the pupillary response to light is impaired while constriction during near effort is relatively preserved.

Bickerstaff Brainstem Encephalitis

Bickerstaff brainstem encephalitis overlaps clinically and immunologically with Fisher syndrome.

Characteristic features include:

• Ophthalmoplegia
• Ataxia
• Impaired consciousness
• Hyperreflexia

The presence of altered consciousness and pyramidal tract features helps distinguish BBE from typical Fisher syndrome.

Diagnostic Tests and Interpretation

Lumbar Puncture

The classic cerebrospinal fluid finding is albuminocytologic dissociation:

Elevated CSF protein with few or no white blood cells.

Importantly, CSF protein may remain normal during the first several days of illness. Therefore, a normal early lumbar puncture does not exclude GBS.

Electrodiagnostic Studies

Nerve conduction studies and electromyography may demonstrate a peripheral neuropathy with demyelinating features.

Findings may include:

• Slowed conduction velocity
• Prolonged distal motor latency
• Conduction block
• Prolonged or absent F waves

Some GBS variants predominantly produce axonal abnormalities rather than demyelination.

Anti-GQ1b Antibody

Serum anti-GQ1b IgG antibody is strongly associated with Fisher syndrome and is detected in more than 85% of typical cases.

It is particularly associated with:

• Ophthalmoplegia
• Ataxia

Anti-GQ1b antibodies can also occur in related GBS-spectrum disorders, including Bickerstaff brainstem encephalitis.

Imaging

GBS and Fisher syndrome are primarily clinical diagnoses supported by CSF and electrophysiologic findings.

MRI is principally useful for excluding alternative diagnoses.

Important alternatives include:

• Brainstem infarction
• Brainstem hemorrhage
• Brainstem encephalitis
• Demyelinating disease
• Structural brainstem lesions
• Wernicke encephalopathy

Brain MRI is frequently normal in GBS and Fisher syndrome.

Occasionally, MRI may demonstrate enhancement of cranial nerves or nerve roots.

Pathological Findings

Typical pathology demonstrates:

• Perivenular inflammatory infiltrates
• Segmental demyelination of peripheral nerves
• Variable axonal degeneration

Differential Diagnosis

Important differential diagnoses include:

• Myasthenia gravis
• Brainstem infarction
• Brainstem hemorrhage
• Brainstem encephalitis
• Brainstem tumor or other mass lesion
• Multiple sclerosis or another demyelinating disorder
• Wernicke encephalopathy
• Botulism
• Cavernous sinus disease

In a patient presenting with acute bilateral ophthalmoplegia, ataxia, and areflexia, Fisher syndrome should be strongly considered.

Treatment

Guillain–Barré Syndrome

Two established disease-modifying treatments are used for significant GBS:

Intravenous Immunoglobulin (IVIG)

IVIG is a standard first-line therapy.

Plasma Exchange

Plasmapheresis/plasma exchange is also an effective first-line treatment.

Both treatments can accelerate recovery in appropriately selected patients.

Routine corticosteroid monotherapy is not an effective treatment for classic GBS.

Fisher Syndrome

Fisher syndrome generally has an excellent spontaneous recovery rate.

Because the disease is uncommon and frequently self-limited, evidence supporting specific immunotherapy is less robust than for classic GBS.

Patients with severe disease, respiratory or bulbar involvement, substantial overlap with classic GBS, or Bickerstaff-spectrum disease require particularly close neurologic assessment.

General Management

GBS management extends well beyond immunotherapy.

Important supportive measures include:

• Respiratory monitoring
• Cardiac monitoring
• Monitoring for autonomic instability
• Thrombosis prevention when appropriate
• Physical and occupational rehabilitation
• Nutritional and swallowing support when required
• Prevention of pressure injuries and other complications of immobility

Management of Diplopia

Acute diplopia can be managed symptomatically with:

• Monocular occlusion
• Temporary prisms when appropriate

Persistent ocular misalignment should generally be observed initially because substantial spontaneous recovery may occur.

Corneal Protection

Facial weakness and incomplete eyelid closure can cause exposure keratopathy.

Patients may require:

• Frequent ocular lubrication
• Lubricating ointment
• Eyelid taping or other protective measures when necessary

The cornea should be monitored closely when facial paresis is severe.

Surgery

Surgery is rarely required during the acute disease.

If recovery eventually plateaus with persistent disabling strabismus, ophthalmoplegia, or ptosis, appropriately selected patients may undergo:

• Strabismus surgery
• Eyelid surgery

Surgery should generally be deferred until the neurologic and ocular alignment abnormalities have become stable.

Inpatient Considerations

Admission

Most patients with classic GBS require hospitalization.

Relatively mild and stable Fisher syndrome may occasionally be managed without admission, but careful neurologic assessment is required because overlap with more generalized GBS can occur.

⚠️ Emergency concern: Progressive weakness, bulbar dysfunction, declining respiratory function, severe autonomic instability, or cardiac arrhythmia requires intensive monitoring and potentially ICU management.

Respiratory Monitoring

Respiratory status should be assessed repeatedly because deterioration may occur rapidly.

Progressive respiratory failure requires early airway management and mechanical ventilation rather than waiting for overt respiratory collapse.

Autonomic Dysfunction

GBS can produce substantial autonomic instability, including:

• Bradycardia
• Tachycardia
• Cardiac arrhythmias
• Blood pressure fluctuations
• Other dysautonomic manifestations

Continuous cardiac monitoring may therefore be necessary in significant disease.

Rehabilitation

Physical and occupational therapy are important components of recovery.

Rehabilitation helps maintain joint mobility, prevent complications of immobility, and maximize recovery of strength and function.

Follow-Up

Patients should receive continued neurologic follow-up until recovery is complete or their neurologic deficits have clearly plateaued.

Patients with ophthalmoplegia require ophthalmologic or neuro-ophthalmologic follow-up when diplopia, ptosis, pupillary abnormalities, or exposure keratopathy persists.

Prognosis

Fisher Syndrome

The prognosis is generally excellent.

Recovery often begins within approximately 2 weeks, and substantial recovery commonly occurs within 3 months, although the exact course varies.

Guillain–Barré Syndrome

Most patients experience substantial neurologic recovery, although recovery may require weeks to months.

A subset is left with persistent weakness, sensory symptoms, fatigue, or other neurologic deficits.

Some patients experience recurrent episodes or evolve into a chronic immune-mediated neuropathy such as chronic inflammatory demyelinating polyneuropathy (CIDP).

Key Ophthalmology Points

The most important ophthalmic association is Fisher syndrome, characterized by the triad of ophthalmoplegia, ataxia, and areflexia.

Acute bilateral or complete ophthalmoplegia—particularly when accompanied by gait ataxia and absent reflexes—should prompt consideration of Fisher syndrome and testing for anti-GQ1b antibodies.

Despite the dramatic ophthalmoplegia, the ocular motor prognosis in Fisher syndrome is generally very good.